Tests a brain protection device during heart valve replacement procedures
Tests a device that catches debris in the brain during aortic valve replacement, in adults.
Plain-language title generated from the registry record
Registry title: Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)
Key facts
- Where
- Clayton, AustraliaSee the site
Where in Australia
- Victorian Heart HospitalClayton, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Transverse Medical, Inc.
- Trial code
- NCT06962371
- Record updated
- 8 May 2025
- Original description
The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.Read full original descriptionShow less
GUARDIAN Australian Feasibility Study: Safety and Feasibility
The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.
Inclusion: The patient is ≥18 years of age; The patient meets indications for Transcatheter Aortic Valve Replacement (TAVR); The patient is willing to comply with protocol-specified follow-up evaluations; The patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board or Ethics Committee.
Exclusion: Anatomy that precludes safe delivery and retrieval of the investigational device; Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period; Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up; Anatomy that precludes safe delivery and retrieval of the investigational device; Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period; Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up; Contraindications to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure); Patients with uncontrolled bleeding disorders; Patients with uncontrolled bleeding disorders; TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval); Patients who are pregnant, as confirmed by a positive pregnancy test; General Exclusion Criteria; TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval); Patients who are pregnant, as confirmed by a positive pregnancy test; Magnetic resonance imaging exclusion criteria:; Body Mass Index (BMI) and/or total body weight precluding imaging in scanner; High risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g., subjects with pre-existing bifascicular block or complete right bundle branch block plus any degree of AV block); Existing or planned implantation of a pacemaker or defibrillator implantation within the first 3 days after TAVR; Claustrophobia precluding MRI scanning.